The stock of IN8bio Inc (INAB) has gone up by 15.87% for the week, with a 31.33% rise in the past month and a -26.41% drop in the past quarter. The volatility ratio for the week is 13.21%, and the volatility levels for the past 30 days are 14.57% for INAB. The simple moving average for the past 20 days is 12.51% for INAB’s stock, with a -51.89% simple moving average for the past 200 days.
Is It Worth Investing in IN8bio Inc (NASDAQ: INAB) Right Now?
Company’s 36-month beta value is 0.00.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INAB is 49.63M, and currently, short sellers hold a 2.69% ratio of that floaft. The average trading volume of INAB on December 03, 2024 was 1.11M shares.
INAB) stock’s latest price update
IN8bio Inc (NASDAQ: INAB) has experienced a rise in its stock price by 20.77 compared to its previous closing price of 0.30. However, the company has seen a gain of 15.87% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at 23.62% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.16% of loss for the given period.
Volatility was left at 14.57%, however, over the last 30 days, the volatility rate increased by 13.21%, as shares surge +28.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.09% upper at present.
During the last 5 trading sessions, INAB rose by +15.87%, which changed the moving average for the period of 200-days by -66.55% in comparison to the 20-day moving average, which settled at $0.3271. In addition, IN8bio Inc saw -73.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INAB
Current profitability levels for the company are sitting at:
- -8.5 for the present operating margin
- 0.5 for the gross margin
The net margin for IN8bio Inc stands at -8.5. The total capital return value is set at -2.58. Equity return is now at value -241.97, with -151.16 for asset returns.
Currently, EBITDA for the company is -28.5 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 7.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
In a nutshell, IN8bio Inc (INAB) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
